For the most up to date news, please follow us on LinkedIn via the link below


Ghent University scientists launch CEPI-funded project ‘spin-freezing’ vaccines

Ghent University will receive up to US $1.9 million to test the performance of optimised mRNA vaccines, developed on the university’s specialised mRNA Galsomes platform, in preclinical models after ‘spin-freezing’ the vaccines. Pioneered by RheaVita, a spin-off company of Ghent University, spin-freezing is a novel alternative to the traditional freeze-drying method. The research will be supported by Flanders Institute for Biotechnology (VIB).

Read More

Coriolis Pharma and RheaVita join forces in collaboration for continuous and controlled freeze-drying technology

Coriolis Pharma extends its service portfolio by integrating RheaVita’s single vial unit (SVU) technology for continuous and controlled freeze-drying to stabilize novel modalities as part of biologics drug product development for clients.

Read More

RheaVita Closes EUR 2.5 million Series A Financing Co-Led by Novalis Biotech Acceleration and PMV

RheaVita, a company pioneering continuous freeze-drying technology for biopharmaceutical products, announced today that the company has closed a EUR 2.5 million Series A Financing.

Read More